Clinical trial
Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
NCT00383851 · Attenuon, Industry · Unknown status
Key facts
| NCT number | NCT00383851 |
|---|---|
| Title | Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma |
| Official title | A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma |
| Lead sponsor | Attenuon, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | ATN-224, Temozolomide |
| Enrollment | 60 |
| Start date | Sep 1, 2006 |
| Completion | Sep 1, 2008 |
| First posted | Oct 4, 2006 |
| Last update posted | Dec 6, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: